JL
Therapeutic Areas
Alkermes Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Sodium oxybate extended-release oral suspension | Idiopathic Hypersomnia (Adults) | Phase 3 |
| Olanzapine and samidorphan (Lybalvi) | Schizophrenia and Bipolar I Disorder (Pediatric) | Phase 3 |
| Alixorexton (ALKS 2680) | Narcolepsy Type 1 | Phase 2 |
Leadership Team at Alkermes
RP
Richard Pops
Chairman and Chief Executive Officer
BJ
Blair Jackson
Executive Vice President, Chief Operating Officer
JR
Joshua Reed
Chief Financial Officer
CH
Craig Hopkinson, M.D.
Executive Vice President, Research & Development and Chief Medical Officer
DG
David Gaffin
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
TN
Todd Nichols
Senior Vice President, Chief Commercial Officer
SS
Stephen Schiavo
Senior Vice President, Chief Human Resources Officer
JS
James Schoener
Senior Vice President, Business Development and Alliance Management
SC
Sandy Coombs
Senior Vice President, Corporate Affairs and Investor Relations
JH
Jeffrey Harris
Senior Vice President & General Manager, Psychiatry/Addiction Business Unit